SONN Sonnet BioTherapeutics Holdings, Inc. Stock Quote

SONN [NASD]

Sonnet BioTherapeutics Holdings, Inc.

Index	-	P/E	-	EPS (ttm)	-8.87	Insider Own	0.10%	Shs Outstand	16.20M	Perf Week	-2.47%
Market Cap	25.60M	Forward P/E	-	EPS next Y	-1.27	Insider Trans	0.00%	Shs Float	15.34M	Perf Month	-24.04%
Income	-68.50M	PEG	-	EPS next Q	-	Inst Own	2.70%	Short Float	1.91%	Perf Quarter	-47.85%
Sales	5.70M	P/S	4.49	EPS this Y	89.10%	Inst Trans	2.10%	Short Ratio	0.23	Perf Half Y	-36.55%
Book/sh	-0.14	P/B	-	EPS next Y	-14.40%	ROA	-592.40%	Target Price	-	Perf Year	-63.26%
Cash/sh	0.14	P/C	11.13	EPS next 5Y	-	ROE	-	52W Range	1.44 - 7.89	Perf YTD	-29.15%
Dividend	-	P/FCF	-	EPS past 5Y	45.70%	ROI	-	52W High	-79.97%	Beta	0.74
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	4.50%	52W Low	9.72%	ATR	0.18
Employees	9	Current Ratio	0.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.42	Volatility	10.84% 10.04%
Optionable	No	Debt/Eq	-	EPS Q/Q	99.50%	Profit Margin	-	Rel Volume	0.54	Prev Close	1.46
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.25M	Price	1.58
Recom	2.00	SMA20	-17.45%	SMA50	-26.24%	SMA200	-37.73%	Volume	669,164	Change	8.22%

May-10-21 06:30AM	Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP) ACCESSWIRE
May-03-21 06:00AM	Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics ACCESSWIRE -12.66%
Mar-29-21 04:30PM	Sonnet BioTherapeutics Provides 2021 Business Update ACCESSWIRE
Mar-22-21 07:00AM	Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations ACCESSWIRE
Feb-16-21 08:10AM	Sonnet BioTherapeutics Provides Fiscal Year 2021 First Quarter Business and Earnings Update ACCESSWIRE
Feb-03-21 06:30AM	Sonnet BioTherapeutics Announces Abstract Accepted for Presentation at AACR 2021 Annual Meeting ACCESSWIRE
Feb-01-21 06:30AM	Sonnet BioTherapeutics Completes Successful Repeat Dose Study of SON-1010 in Non-Human Primates ACCESSWIRE
Jan-25-21 06:30AM	Sonnet BioTherapeutics Announces the Successful Completion of a Non-human Primate Toxicology Study of SON-080 ACCESSWIRE
Dec-17-20 06:30AM	Sonnet BioTherapeutics Provides Fiscal Year 2020 Business and Earnings Update ACCESSWIRE -6.02%
Nov-30-20 08:30AM	Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010 ACCESSWIRE
Sep-01-20 08:30AM	Sonnet Announces New Preclinical Data for SON-1010 (Interleukin 12-F(H)AB) ACCESSWIRE
Aug-25-20 07:30AM	Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants ACCESSWIRE -18.97%
Aug-24-20 07:37AM	Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod SmarterAnalyst +48.29%
Aug-14-20 07:30AM	Sonnet BioTherapeutics Provides Fiscal Year Third Quarter Business and Earnings Update ACCESSWIRE
Aug-04-20 07:35AM	Sonnet BioTherapeutics Announces At-The-Market Warrant Repricing and Exchange Resulting in Expected Gross Proceeds to the Company of up to $10.5 Million ACCESSWIRE
07:30AM	Sonnet BioTherapeutics Signs Letter of Intent for Potential Licensing of Neuropathies Asset to New Life Therapeutics ACCESSWIRE
Jul-20-20 07:30AM	Sonnet Biotherapeutics Announces Positive Preclinical Results from an Initial Efficacy Study Exploring the Combination of Granulocyte-Macrophage Colony-Stimulating Factor with Interleukins 18 and 12 ACCESSWIRE
Jul-15-20 07:30AM	Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference ACCESSWIRE +10.03%
May-18-20 07:30AM	Sonnet BioTherapeutics Holdings Provides Business and Earnings Update ACCESSWIRE
Apr-06-20 07:30AM	Sonnet BioTherapeutics Announces Formation of Scientific Advisory Board ACCESSWIRE

Sonnet BioTherapeutics Holdings, Inc., an oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding (FHAB) technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate includes SON-080, a human version of low dose Interleukin-6 (IL-6), which has completed Phase I trials for the treatment of patients with chemotherapy-induced peripheral neuropathy. The company is also developing SON-081, a low dose IL-6 for the treatment of patients with diabetic peripheral neuropathy and is under phase I trials; SON-1010, a FHAB derived compound, which utilizes a human version of Interleukin-12 (IL-12) is under pre-clinical trial, as well as SON-1210, a bi-specific construct that combines FHAB with IL-12 and human Interleukin-15 for the treatment of solid tumor is under pre-clinical trial. In addition, it develops SON-2014, a bi-specific combination of granulocyte-macrophage colony stimulating factor and Interleukin-18 for the treatment of cancer; and SON-3015, a bi-specific combination of anti-IL6 and anti-tumor growth factor beta for tumor and bone metastases. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience